Drug Insights

Maximize Your Synapse Use: Your Guide to Searching Meclizine

11 February 2024
2 min read

Meclizine is a small molecule drug that acts as an antagonist of histamine (H1) receptors. It is marketed under the trade names Antivert, Bonine, and Navicalm and is approved for the treatment of motion sickness, nausea, and vomiting. It's a white or slightly yellowish, crystalline powder that was first approved by Casper Pharma on February 14, 1957, in the United States. As an H1 receptor antagonist, meclizine is thought to work by reducing the activity of histamine in the brain, which can help to alleviate the symptoms of motion sickness and other conditions. There is always available in tablet form and is typically taken by mouth. It is important to follow the dosing instructions provided by a healthcare provider and to be aware of any potential side effects or drug interactions that may occur. Click on the image below to begin the exploration journey of Meclizine through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Bio-Thera Solutions Initiates Phase 1B/2A Study for BAT6026 Monoclonal Antibody in Eczema Treatment
Latest Hotspot
3 min read
Bio-Thera Solutions Initiates Phase 1B/2A Study for BAT6026 Monoclonal Antibody in Eczema Treatment
9 February 2024
Bio-Thera Solutions has launched an early-stage clinical study, specifically Phase 1B/2A, for its novel monoclonal antibody, BAT6026, aimed at OX40 for treating individuals experiencing moderate to intense eczema.
Read →
Master Rosuvastatin Search on Synapse
Drug Insights
2 min read
Master Rosuvastatin Search on Synapse
9 February 2024
Rosuvastatin, sold as Ezallor and Crestor, is a small molecule inhibiting liver cholesterol synthesis by blocking HMG-CoA reductase enzyme.
Read →
New Insights: Vabysmo Effectively Treats Retinal Swelling in Retinal Vein Occlusion Patients
Latest Hotspot
3 min read
New Insights: Vabysmo Effectively Treats Retinal Swelling in Retinal Vein Occlusion Patients
9 February 2024
Recent findings on Genentech's drug Vabysmo indicate persistent efficacy in reducing retinal swelling and enhancing eyesight for those with Retinal Vein Occlusion.
Read →
Unveiling Escitalopram: How to Search for it on Synapse
Drug Insights
2 min read
Unveiling Escitalopram: How to Search for it on Synapse
9 February 2024
Escitalopram, marketed under the trade name Esertia, is an orally administered selective serotonin reuptake inhibitor.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.